Strategic Advisors LLC Boosts Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Strategic Advisors LLC grew its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 137.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,198 shares of the company's stock after acquiring an additional 40,116 shares during the quarter. Strategic Advisors LLC's holdings in Cellebrite DI were worth $1,345,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CLBT. Gen Wealth Partners Inc purchased a new position in Cellebrite DI in the 4th quarter valued at $85,000. NewEdge Advisors LLC lifted its stake in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after buying an additional 3,352 shares in the last quarter. Polen Capital Management LLC acquired a new position in Cellebrite DI during the fourth quarter worth about $222,000. Victory Capital Management Inc. acquired a new position in Cellebrite DI during the fourth quarter worth about $234,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Cellebrite DI during the 1st quarter valued at about $269,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CLBT. Needham & Company LLC restated a "buy" rating and set a $24.00 target price on shares of Cellebrite DI in a report on Friday, June 6th. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $22.43.

Cellebrite DI Stock Performance

CLBT opened at $15.93 on Tuesday. The business's 50 day moving average price is $18.10 and its 200 day moving average price is $19.92. The stock has a market capitalization of $3.81 billion, a PE ratio of -11.46, a P/E/G ratio of 4.27 and a beta of 1.32. Cellebrite DI Ltd. has a one year low of $11.47 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The company's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.08 EPS. As a group, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.